Carlos Chaccour is internist with a special interest in global health, rural medicine and poverty-related diseases. He has more than 13 years of clinical experience and has worked in the field in indigenous communities in the Venezuelan Amazon and in Mozambique. For the last nine years, his research focus has been the development of a new paradigm for malaria vector control, the use of ivermectin, a safe anti-helminthic drug that is given orally to humans or animals and can kill mosquitoes feeding on those treated subjects. He has conducted clinical trials, animal models and basic research projects on this field. He has also tried to generate a research consensus for this topic so the investments done can generate solid results capable of shaping policy. Additionally, he has collaborated with the Global Malaria Programme on the evaluation of this potential new tool. He has ongoing projects or collaborations in Bolivia, Cameroon, Mozambique and Tanzania.
Carlos Chaccour obtained his MD from the Universidad Central de Venezuela in 2004. In 2007 he was awarded a Chevening scholarship for his MSc at the London School of Hygiene and Tropical Medicine. He received his PhD degree in 2015 from the University of Navarra, the subject was the potential role of ivermectin as a complementary tool for malaria elimination and obtained a specialist degree in Internal Medicine from the Clinica Universidad de Navarra in 2016. He additionally holds a position as visiting scholar at the Instituto de Salud Tropical Universidad de Navarra.
Lines of Research
- Malaria epidemiology
- Vector control
- Chaccour CJ, et al: Cytochrome P450 inhibition/ABC transporter modulation simultaneously enhances ivermectin pharmacokinetics in the host and pharmacodynamics in Anopheles gambiae. In press
- Chaccour CJ, Hammann F, Rabinovich NR: Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety. Malar J. 2017; 16:161
- Chaccour CJ, Rabinovich NR: Ivermectin to reduce malaria transmission II. Considerations regarding clinical development pathway. Malar J. 2017; 16:166
- Chaccour CJ, Rabinovich NR: Ivermectin to reduce malaria transmission III. Considerations regarding regulatory and policy pathways. Malar J. 2017; 16: 162
- Chaccour C, Lines J, Whitty CJ. Effect of ivermectin on Anopheles gambiae mosquitoes fed on humans: the potential of oral insecticides in malaria control. J Infect Dis. 2010; 202:113-6.